Search Results - "Greco, F. A."

Diagnostic and therapeutic management of cancer of an unknown primary by Pavlidis, N., Briasoulis, E., Hainsworth, J., Greco, F.A.

“…Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all malignant neoplasms and is therefore one of the 10 most frequent cancer…”
Get full text

Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes by Greco, F.A., Oien, K., Erlander, M., Osborne, R., Varadhachary, G., Bridgewater, J., Cohen, D., Wasan, H.

“…This paper explores the enigma of cancer of unknown primary (CUP) in relation to rapidly improving molecular diagnostic approaches. It is based on the first…”
Get full text

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation by Muggia, F M, Hainsworth, J D, Jeffers, S, Miller, P, Groshen, S, Tan, M, Roman, L, Uziely, B, Muderspach, L, Garcia, A, Burnett, A, Greco, F A, Morrow, C P, Paradiso, L J, Liang, L J

“…A phase II study of liposomal doxorubicin was conducted in patients with ovarian cancer who failed to respond to platinum- and paclitaxel-based regimens…”
Get more information

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Fizazi, K., Greco, F.A., Pavlidis, N., Daugaard, G., Oien, K., Pentheroudakis, G.

Get full text

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer by Hainsworth, J D, Burris, 3rd, H A, Erland, J B, Thomas, M, Greco, F A

“…Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients treated with a dose of 100 mg/m2 every…”
Get more information

Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Fizazi, K., Greco, F.A., Pavlidis, N., Pentheroudakis, G.

Get full text

Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network by MELUCH, Anthony A, GRECO, F. Anthony, BURRIS, Howard A, O'ROURKE, Timothy, ORTEGA, Gregory, STEIS, Ronald G, MORRISSEY, Lisa H, JOHNSON, Valerie, HAINSWORTH, John D

“…To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel and gemcitabine in patients with advanced transitional-cell carcinoma of the…”
Get full text

Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin by Greco, F. A., Erland, J. B., Morrissey, L. H., Burris, H. A., Hermann, R. C., Steis, R., Thompson, D., Gray, J., Hainsworth, J. D.

“…Purpose: To evaluate the toxicity, response rate and short-term survival associated with the chemotherapy combinations of docetaxel plus cisplatin or…”
Get full text

Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial by HAINSWORTH, John D, BURRIS, Howard A, YARDLEY, Denise A, BRADOF, James E, GRIMALDI, Manuel, KALMAN, Leonard A, SULLIVAN, Tim, BAKER, Margaret, ERLAND, Joan B, GRECO, F. Anthony

“…To evaluate the efficacy and toxicity of docetaxel administered weekly to elderly or poor-performance status patients with advanced breast cancer. Forty-one…”
Get full text

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer by Hainsworth, J D, Thompson, D S, Greco, F A

“…Paclitaxel is an active single agent when administered as a 24-hour continuous infusion in the treatment of stage IV non-small-cell lung cancer. We evaluated…”
Get more information

Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide by Hainsworth, J D, Erland, J B, Kalman, L A, Schreeder, M T, Greco, F A

“…To evaluate the efficacy and toxicity of a novel chemotherapy combination that includes paclitaxel, carboplatin, and extended-schedule etoposide in the…”
Get more information

Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review by Pentheroudakis, George, Greco, F.A, Pavlidis, Nicholas

“…Summary Background Gene expression profiling platforms were recently shown to accurately assign cancer of unknown primary (CUP) to a primary tissue of origin,…”
Get full text

Docetaxel (Taxotere) administered in weekly schedules by Greco, F A

“…The administration of a weekly low-dose taxane markedly reduces the severity of myelosuppression compared with a once-every-3-week schedule and allows the dose…”
Get more information

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A minnie pearl cancer research network Phase II trial by HAINSWORTH, J. D, BURRIS, H. A, LITCHY, S, MORRISSEY, L. H, BARTON, J. H, BRADOF, J. E, GRECO, F. A

“…Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. In…”
Get full text

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities by Hainsworth, J D, Gray, J R, Stroup, S L, Kalman, L A, Patten, J E, Hopkins, L G, Thomas, M, Greco, F A

“…In two sequential phase II studies, we evaluate the feasibility and efficacy of adding paclitaxel to a standard platinum/etoposide regimen in the first-line…”
Get more information

Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim by Weaver, C. H., Birch, R., Greco, F. A., Schwartzberg, L., McAneny, B., Moore, M., Oviatt, D., Redmond, J., George, C., Alberico, T., Johnson, P., Buckner, C. D.

“…The effects of different doses of filgrastim on yields of CD34+ peripheral blood stem cells were evaluated in patients with breast cancer. 55 were randomized…”
Get full text

Bioavailability of low-dose oral etoposide by Hande, K R, Krozely, M G, Greco, F A, Hainsworth, J D, Johnson, D H

“…To determine the bioavailability of oral etoposide capsules administered at doses of 100 mg and 400 mg. The bioavailability of oral etoposide was determined by…”
Get more information

Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol by Einhorn, L H, Williams, S D, Loehrer, P J, Birch, R, Drasga, R, Omura, G, Greco, F A

“…Four courses of PVP16B (cisplatin plus etoposide [VP-16] plus bleomycin) has been standard chemotherapy for disseminated germ cell tumors at Indiana University…”
Get more information

Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer by Greco, F A, Figlin, R, York, M, Einhorn, L, Schilsky, R, Marshall, E M, Buys, S S, Froimtchuk, M J, Schuller, J, Schuchter, L, Buyse, M, Ritter, L, Man, A, Yap, A K

“…To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) and recombinant human interferon alfa-2a ([IFN alpha 2a] Roferon-A;…”
Get more information

Overexpression of Her-2 in Patients With Poorly Differentiated Carcinoma or Poorly Differentiated Adenocarcinoma of Unknown Primary Site by HAINSWORTH, J. D, LENNINGTON, W. J, GRECO, F. A

“…To determine the frequency of Her-2 overexpression in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary…”
Get full text